Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 19/20 | 1.00 |
| ▸ | ESRRB | O95718 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ESRRG | P62508 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.60 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650140 | 1.00 | ESRRA (1.00) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2699107 | 1.00 | ESRRA (1.00) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL31188051 | 1.00 | ESRRA (1.00) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8156842 | 0.92 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380995 | 0.92 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380997 | 0.92 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2705253 | 0.92 | ESRRA (0.84) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2705251 | 0.92 | ESRRA (0.84) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4435911 | 0.92 | ESRRA (0.84) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4435916 | 0.92 | ESRRA (0.84) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649963-A2 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-3131588-B1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240368179-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240299366-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3302572-B3 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| CN-115974840-A | Human cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | GAUL MICHAEL (US) | 2012-05-03 | — | — | US | disclosed |
| US-8119669-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | disclosed |
| EP-2132188-B1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-14 | — | — | EP | disclosed |
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | JANSSEN PHARAMCEUTICA N.V. (BE) | 2011-09-29 | — | — | US | disclosed |
| US-7846953-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2010-12-07 | — | — | US | disclosed |
| EP-2129668-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2009-12-09 | — | — | EP | disclosed |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008109727-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | ESR2, ESRRA, ESRRB | ESRRA 2/4885ESRRB 3/4885ESR1 6/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ESRRA 1369/4885ESRRB 1112/4885ESR1 2847/4885 |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 6/4885 |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ESRRA 1369/4885ESRRB 1112/4885ESR1 2847/4885 |
| US-20240299366-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | ESRRA 2193/4885ESRRB 2385/4885ESR1 2136/4885 |
| US-20240368179-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE | CRBN, MDM2, UBE2N | ESRRA 2262/4885ESRRB 2603/4885ESR1 2019/4885 |
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | ESRRA 1369/4885ESRRB 1112/4885ESR1 2847/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | ESRRA 2193/4885ESRRB 2385/4885ESR1 2136/4885 |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.